Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1,217.58% | -20.15% | 10.50% | -36.31% | 505.22% |
| Total Depreciation and Amortization | 4.15% | 2.55% | 0.35% | -2.15% | -1.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,083.94% | 18.77% | 304.25% | -83.53% | 37.88% |
| Change in Net Operating Assets | -264.86% | 90.50% | -307.00% | 68.59% | -990.55% |
| Cash from Operations | 4.36% | 363.41% | -56.89% | -44.90% | 128.69% |
| Capital Expenditure | -101.36% | -58.84% | 6.26% | -91.83% | 15.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.42% | -8,764.30% | 73.27% | -102.70% | 503.85% |
| Cash from Investing | 14.23% | -1,322.98% | 31.28% | -107.42% | 454.44% |
| Total Debt Issued | -- | -- | -- | -100.11% | -- |
| Total Debt Repaid | -- | -- | -- | 95.42% | -- |
| Issuance of Common Stock | -53.92% | 155.08% | -68.45% | -46.36% | -4.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 7.85% | 4.65% | -95.48% | 1,579.59% | -7.91% |
| Cash from Financing | -49.36% | 130.60% | -65.32% | 110.79% | -640.80% |
| Foreign Exchange rate Adjustments | 48.51% | 65.39% | -23.91% | -514.99% | -103.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,675.62% | -105.49% | -67.70% | -55.96% | 302.66% |